| |
Financial Year 2008 - 2009
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED
31st MARCH 2008
| (Rs.in Million ) |
| Sl. No |
Particulars |
Year ended 31st March |
2008
(Audited) |
2007 (Audited) |
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
|
Net Sales / Income from Operations
-Sales(net)
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Other Income
Total Income (1+2)
Expenditure
a) (Increase) / Decrease in Stock in trade and Work in Programs
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortisation
f)Other Expenditure
Total Expenditure
Profit before R&D & Interest (3-5)
Research and Development Expenditure
Interest
Profit from Ordinary Activities before tax & Exceptional item (6-7-8)
Provision for impairment of goodwill (Refer note 3)
Profit/(Loss) before tax and after exceptional item (9-10)
Tax expense (net)
Profit /(Loss) after Tax & Exceptional Item before Minority Interest and share in Associate (11-12)
Less : Minority Interest
Less : Share of Profit/ (Loss) in Associate
Net Profit/ (Loss) after Tax and Exceptional Item (13-14-15)
Paid-up equity share capital (Face value - Rs.2 each)
Reserves excluding revaluation reserves
Earning Per Share (Not annualised) - (Face Value - Rs.2 each)
On Profit/(Loss) after Tax :
- Before Exceptional Item
-Basic
-Diluted
- After Exceptional Item
-Basic
-Diluted
|
17,280.67
66.09
269.13
17,615.89
244.75
17,860.64
(816.81)
6,596.72
3220.12
1882.56
605.51
3,198.89
14,686.99
3,173.65
1,423.27
960.40
789.98
4,871.21
(4,081.23)
529.69
(4,610.92)
41.95
(0.30)
(4,569.27)
309.18
6,538.79
1.96
1.95
(29.59)
(29.59)
|
16,480.27
38.24
268.39
16,786.90
237.71
17,024.61
2.83
4,943.44
4,034.00
1,773.35
540.70
2,997.12
14,291.44
2,733.17
1,007.56
704.19
1,021.42
-1,021.42
264.89
756.53
6.57
-763.10
308.24
10,193.55
4.96
4.93
4.96
4.93
|
Segment Information :
Segment Revenue :
- Pharmaceuticals
- Medical Supplies
Net Segment Revenue
Segment Results :
Profit before tax and interest from each segment
- Pharmaceuticals
- Medical Supplies
Total
Less:Interest
Total Profit before tax
Capital Employed
- Pharmaceuticals
- Medical Supplies
- Unallocated
Total Capital Employed
|
15,706.71
1,573.96
17,280.67
1,693.27
57.11
1,750.38
(960.40)
789.98
15,674.06
482.50
7,977.07
24,133.63
|
14,283.02
2,197.25
16,480.27
1,627.41
98.20
1,725.61
(704.19)
1,021.42
15,403.30
188.21
11,920.21
27,511.72
|
|
| Notes : |
|
| 1. |
|
The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 30th June 2008.
|
| 2. |
|
The figures for the previous year have been rearranged / regrouped wherever necessary to conform to current year's presentation. |
| 3. |
|
Exceptional item represents impairment loss on Goodwill of Rs. 4,871.21 Millions pertaining to the investment in Docpharma, held by Matrix Laboratories NV, a step down subsidiary of the Company. This impairment loss was triggered by changes in underlying business conditions of Docpharma group. The impairment loss has been determined on the basis of valuation carried out by independent professionals.
|
|
|
|
| place: Secunderabad |
|
Rajiv Malik |
|
| Date: 30th June, 2008 | |
Managing Director |
|
|
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED
31st MARCH 2008
| (Rs.in Million ) |
| Sl. No |
Particulars |
Year ended 31st March |
2008
(Audited) |
2007
(Audited) |
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
|
Net Sales / Income from Operations
-Exports
-Domestic
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Other Income
Total Income (1+2)
Expenditure
a) (Increase) / Decrease in Stock in trade and Work in Programs
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortisation
f)Other Expenditure
Total Expenditure
Profit before R&D & Interest (3-5)
Research and Development Expenditure (including depreciation)
Interest
Profit from Ordinary Activities before Exceptional item & tax(5-6-7)
Provision for diminution in the value of investment in subsidiary (Refer note 3)
Profit/(Loss) before tax and after exceptional item (8-9)
Tax expense (net)
Net Profit/(Loss) after tax (10-11)
Paid-up equity share capital (Face value - Rs 2/- each)
Reserves excluding revaluation reserves
Earning Per Share (EPS) (Not annualised)
On Profit/(Loss) after Tax :
- Before Exceptional Item
- Basic
- Diluted
- After Exceptional Item
- Basic
- Diluted
Public shareholding
- Number of shares
- Percentage of shareholding
|
6206.64
3179.69
132.18
269.13
9787.64
201.75
9989.39
(725.81)
5336.69
35.40
703.81
295.40
1599.11
7244.60
2744.79
1064.08
267.69
1413.02
4011.83
(2598.81)
384.76
(2983.57)
309.18
6,489.94
6.66
6.64
(19.32)
(19.32)
36,876,696
23.85% |
5,051.77
2,440.44
88.33
268.39
7,848.93
162.08
8,011.01
(28.22)
3,789.51
99.03
598.38
250.71
1,271.52
5,980.93
2,030.08
800.92
154.01
1,075.15
-
1075.15
79.02
996.13
308.24
9388.77
6.48
6.43
6.48
6.43
36,405,635
23.62% |
|
| Notes : |
|
| 1. |
|
The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 30th June 2008.
|
| 2. |
|
The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
|
| 3. |
|
Exceptional item represents a diminution of Rs. 4011.83 Millions to the carrying cost of investment in Docpharma, held by Matrix Laboratories NV, a stepdown subsidiary of the company. This diminution was triggered by changes in underlying business conditions of Docpharma group. The charge on account of diminution has been determined on the basis of valuation carried out by independent professionals.
|
| 4. |
|
During the year, 374,555 Equity Shares of Rs.2/- each at a premium of Rs.141.13, 45,300 Equity Shares of Rs.2/- each at a premium of Rs.142.63 and 51,206 Equity Shares of Rs.2/- each at a premium of Rs.169 /- were allotted on exercise of stock options under the Employee Stock Option Scheme.
|
| 5. |
|
Tax expense includes Current tax of Rs.158.45 Millions ( 2006-07 Rs.45 Millions), adjustment relating to past years of Rs.55.13 Millions (2006-07 Rs.Nil), Deferred tax of Rs.127.93 Millions (2006-07 Rs.61.02 Millions) and Fringe benefit tax of Rs.21 Million (2006-07 Rs.8 Millions) and is net of MAT credit available of Rs.(22.25) Millions (2006-07 Rs.35 Millions).
|
| 6. |
|
The figures for the previous year have been rearranged/regrouped wherever necessary to conform to current year's presentation.
|
| 7. |
|
Summary of Investor Complaints
|
|
|
Opening : Nil , Received during the quarter : 1 , Resolved : 1 , Closing : Nil.
|
|
|
|
| For and on behalf of the Board |
| Place: Secunderabad |
|
Rajiv Malik |
|
| Date : 30th June 2008
| |
Managing Director |
|
|
|
|
|
